Prevalence of oral human papillomavirus by vaccination status among young adults (18–30 years old)

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background Although there is evidence that human papillomavirus (HPV) vaccination may protect against oral HPV infection, no current research has demonstrated this in the general population. Methods We used repeated cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) between 2009 and 2014. Participants 18–30 years who indicated whether they had received the HPV vaccine and provided an adequate oral sample were included (N = 3040). Oral HPV types were grouped by vaccine-type (types 6, 11, 16, 18) and by risk (high or low risk). Chi-square analyses compared oral HPV prevalence by vaccination status. Results Vaccinated adults had a lower prevalence of vaccine-type oral HPV (types 6, 11, 16, 18) compared to unvaccinated adults. Prevalence of non-vaccine high-risk oral HPV was similar between HPV vaccinated and unvaccinated participants. Conclusions HPV vaccination appears to provide protection against vaccine-type oral HPV infection among males and females in the general population.

Original languageEnglish (US)
Pages (from-to)3446-3451
Number of pages6
JournalVaccine
Volume35
Issue number27
DOIs
StatePublished - Jun 14 2017

Fingerprint

Papillomaviridae
young adults
Young Adult
mouth
Vaccination
vaccination
Papillomavirus Infections
Vaccines
vaccines
Human papillomavirus 11
Human papillomavirus 6
Papillomavirus Vaccines
Nutrition Surveys
National Health and Nutrition Examination Survey
Population
infection
Research

Keywords

  • HPV vaccination
  • Oral cancer
  • Oral HPV infection
  • Primary oral cancer prevention

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

@article{afdb1365a9764802b9453a15a87439bf,
title = "Prevalence of oral human papillomavirus by vaccination status among young adults (18–30 years old)",
abstract = "Background Although there is evidence that human papillomavirus (HPV) vaccination may protect against oral HPV infection, no current research has demonstrated this in the general population. Methods We used repeated cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) between 2009 and 2014. Participants 18–30 years who indicated whether they had received the HPV vaccine and provided an adequate oral sample were included (N = 3040). Oral HPV types were grouped by vaccine-type (types 6, 11, 16, 18) and by risk (high or low risk). Chi-square analyses compared oral HPV prevalence by vaccination status. Results Vaccinated adults had a lower prevalence of vaccine-type oral HPV (types 6, 11, 16, 18) compared to unvaccinated adults. Prevalence of non-vaccine high-risk oral HPV was similar between HPV vaccinated and unvaccinated participants. Conclusions HPV vaccination appears to provide protection against vaccine-type oral HPV infection among males and females in the general population.",
keywords = "HPV vaccination, Oral cancer, Oral HPV infection, Primary oral cancer prevention",
author = "Hirth, {Jacqueline M.} and Mihyun Chang and Resto, {Vicente A.} and Fangjian Guo and Berenson, {Abbey B.}",
year = "2017",
month = "6",
day = "14",
doi = "10.1016/j.vaccine.2017.05.025",
language = "English (US)",
volume = "35",
pages = "3446--3451",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "27",

}

TY - JOUR

T1 - Prevalence of oral human papillomavirus by vaccination status among young adults (18–30 years old)

AU - Hirth, Jacqueline M.

AU - Chang, Mihyun

AU - Resto, Vicente A.

AU - Guo, Fangjian

AU - Berenson, Abbey B.

PY - 2017/6/14

Y1 - 2017/6/14

N2 - Background Although there is evidence that human papillomavirus (HPV) vaccination may protect against oral HPV infection, no current research has demonstrated this in the general population. Methods We used repeated cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) between 2009 and 2014. Participants 18–30 years who indicated whether they had received the HPV vaccine and provided an adequate oral sample were included (N = 3040). Oral HPV types were grouped by vaccine-type (types 6, 11, 16, 18) and by risk (high or low risk). Chi-square analyses compared oral HPV prevalence by vaccination status. Results Vaccinated adults had a lower prevalence of vaccine-type oral HPV (types 6, 11, 16, 18) compared to unvaccinated adults. Prevalence of non-vaccine high-risk oral HPV was similar between HPV vaccinated and unvaccinated participants. Conclusions HPV vaccination appears to provide protection against vaccine-type oral HPV infection among males and females in the general population.

AB - Background Although there is evidence that human papillomavirus (HPV) vaccination may protect against oral HPV infection, no current research has demonstrated this in the general population. Methods We used repeated cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) between 2009 and 2014. Participants 18–30 years who indicated whether they had received the HPV vaccine and provided an adequate oral sample were included (N = 3040). Oral HPV types were grouped by vaccine-type (types 6, 11, 16, 18) and by risk (high or low risk). Chi-square analyses compared oral HPV prevalence by vaccination status. Results Vaccinated adults had a lower prevalence of vaccine-type oral HPV (types 6, 11, 16, 18) compared to unvaccinated adults. Prevalence of non-vaccine high-risk oral HPV was similar between HPV vaccinated and unvaccinated participants. Conclusions HPV vaccination appears to provide protection against vaccine-type oral HPV infection among males and females in the general population.

KW - HPV vaccination

KW - Oral cancer

KW - Oral HPV infection

KW - Primary oral cancer prevention

UR - http://www.scopus.com/inward/record.url?scp=85019889177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019889177&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2017.05.025

DO - 10.1016/j.vaccine.2017.05.025

M3 - Article

C2 - 28526331

AN - SCOPUS:85019889177

VL - 35

SP - 3446

EP - 3451

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 27

ER -